MedTrace Logo

Study to Determine Safety and Dose of NJH395 in Non-breast HER2+ Advanced Cancer

NCT03696771 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 18

Last updated 2022-02-04

No results posted yet for this study

Summary

A first-in-human study using NJH395 in non-breast HER2-positive advanced malignancies

Conditions

  • NON-breast HER2+ Malignancies

Interventions

DRUG

NJH395

Immune stimulator antibody conjugate (ISAC), consisting of a monoclonal antibody which targets HER2 conjugated to an immune-stimulatory agent

Sponsors & Collaborators

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-12-27
Primary Completion
2020-10-19
Completion
2020-10-19
FDA Drug
Yes

Countries

  • United States
  • Italy
  • Japan
  • South Korea

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03696771 on ClinicalTrials.gov